• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

结合前列腺健康指数(PHI)和前列腺影像报告和数据系统(PI-RADS)检测前列腺癌的列线图:一项多中心前瞻性研究。

Nomograms Combining PHI and PI-RADS in Detecting Prostate Cancer: A Multicenter Prospective Study.

作者信息

Zhou Yongheng, Fu Qiang, Shao Zhiqiang, Zhang Keqin, Qi Wenqiang, Geng Shangzhen, Wang Wenfu, Cui Jianfeng, Jiang Xin, Li Rongyang, Zhu Yaofeng, Chen Shouzhen, Shi Benkang

机构信息

Department of Urology, Qilu Hospital of Shandong University, Jinan 250012, China.

Department of Urology, Shandong Provincial Hospital, Jinan 250000, China.

出版信息

J Clin Med. 2023 Jan 1;12(1):339. doi: 10.3390/jcm12010339.

DOI:10.3390/jcm12010339
PMID:36615138
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9821430/
Abstract

(1) Background: The study aimed to construct nomograms to improve the detection rates of prostate cancer (PCa) and clinically significant prostate cancer (CSPCa) in the Asian population. (2) Methods: This multicenter prospective study included a group of 293 patients from three hospitals. Univariable and multivariable logistic regression analysis was performed to identify potential risk factors and construct nomograms. Discrimination, calibration, and clinical utility were used to assess the performance of the nomogram. The web-based dynamic nomograms were subsequently built based on multivariable logistic analysis. (3) Results: A total of 293 patients were included in our study with 201 negative and 92 positive results in PCa. Four independent predictive factors (age, prostate health index (PHI), prostate volume, and prostate imaging reporting and data system score (PI-RADS)) for PCa were included, and four factors (age, PHI, PI-RADS, and Log PSA Density) for CSPCa were included. The area under the ROC curve (AUC) for PCa was 0.902 in the training cohort and 0.869 in the validation cohort. The AUC for CSPCa was 0.896 in the training cohort and 0.890 in the validation cohort. (4) Conclusions: The combined diagnosis of PHI and PI-RADS can avoid more unnecessary biopsies and improve the detection rate of PCa and CSPCa. The nomogram with the combination of age, PHI, PV, and PI-RADS could improve the detection of PCa, and the nomogram with the combination of age, PHI, PI-RADS, and Log PSAD could improve the detection of CSPCa.

摘要

(1) 背景:本研究旨在构建列线图以提高亚洲人群中前列腺癌(PCa)和临床显著前列腺癌(CSPCa)的检出率。(2) 方法:这项多中心前瞻性研究纳入了来自三家医院的293例患者。进行单变量和多变量逻辑回归分析以识别潜在风险因素并构建列线图。使用辨别力、校准和临床实用性来评估列线图的性能。随后基于多变量逻辑分析构建了基于网络的动态列线图。(3) 结果:我们的研究共纳入293例患者,其中PCa检测结果为阴性201例,阳性92例。纳入了PCa的四个独立预测因素(年龄、前列腺健康指数(PHI)、前列腺体积和前列腺影像报告和数据系统评分(PI-RADS)),以及CSPCa的四个因素(年龄、PHI、PI-RADS和Log PSA密度)。PCa在训练队列中的ROC曲线下面积(AUC)为0.902,在验证队列中为0.869。CSPCa在训练队列中的AUC为0.896,在验证队列中为0.890。(4) 结论:PHI和PI-RADS的联合诊断可以避免更多不必要的活检,并提高PCa和CSPCa的检出率。年龄、PHI、PV和PI-RADS相结合的列线图可以提高PCa的检测率,年龄、PHI、PI-RADS和Log PSAD相结合的列线图可以提高CSPCa的检测率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c83/9821430/c4625920ddc9/jcm-12-00339-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c83/9821430/e1dd8228d135/jcm-12-00339-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c83/9821430/048ce3e22852/jcm-12-00339-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c83/9821430/c4625920ddc9/jcm-12-00339-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c83/9821430/e1dd8228d135/jcm-12-00339-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c83/9821430/048ce3e22852/jcm-12-00339-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c83/9821430/c4625920ddc9/jcm-12-00339-g003.jpg

相似文献

1
Nomograms Combining PHI and PI-RADS in Detecting Prostate Cancer: A Multicenter Prospective Study.结合前列腺健康指数(PHI)和前列腺影像报告和数据系统(PI-RADS)检测前列腺癌的列线图:一项多中心前瞻性研究。
J Clin Med. 2023 Jan 1;12(1):339. doi: 10.3390/jcm12010339.
2
Based on PI-RADS v2.1 combining PHI and ADC values to guide prostate biopsy in patients with PSA 4-20 ng/mL.基于 PI-RADS v2.1,结合 PHI 和 ADC 值指导 PSA 为 4-20ng/mL 的患者进行前列腺活检。
Prostate. 2024 Mar;84(4):376-388. doi: 10.1002/pros.24658. Epub 2023 Dec 20.
3
How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?如何在 PI-RADS v2 评分≤3 的初次活检无前列腺癌的男性中做出临床决策以避免不必要的前列腺筛查?
Int J Clin Oncol. 2020 Jan;25(1):175-186. doi: 10.1007/s10147-019-01524-9. Epub 2019 Aug 31.
4
Development of a nomogram combining multiparametric magnetic resonance imaging and PSA-related parameters to enhance the detection of clinically significant cancer across different region.开发一种结合多参数磁共振成像和前列腺特异性抗原(PSA)相关参数的列线图,以提高不同区域临床显著性癌症的检测率。
Prostate. 2022 Apr;82(5):556-565. doi: 10.1002/pros.24302. Epub 2022 Jan 31.
5
The potential of a nomogram combined PI-RADS v2.1 and contrast-enhanced ultrasound (CEUS) to reduce unnecessary biopsies in prostate cancer diagnostics.列线图联合 PI-RADS v2.1 评分与超声造影在前列腺癌诊断中减少不必要活检的潜力。
Br J Radiol. 2022 Sep 1;95(1138):20220209. doi: 10.1259/bjr.20220209. Epub 2022 Aug 17.
6
Construction and Comparison of Different Models in Detecting Prostate Cancer and Clinically Significant Prostate Cancer.检测前列腺癌及临床显著性前列腺癌不同模型的构建与比较
Front Oncol. 2022 Jul 12;12:911725. doi: 10.3389/fonc.2022.911725. eCollection 2022.
7
Creating a novel multiparametric magnetic resonance imaging-based biopsy strategy for reducing unnecessary prostate biopsies: a retrospective cohort study.创建一种基于多参数磁共振成像的新型活检策略以减少不必要的前列腺活检:一项回顾性队列研究。
Quant Imaging Med Surg. 2024 Feb 1;14(2):2021-2033. doi: 10.21037/qims-23-875. Epub 2024 Jan 22.
8
The function of Prostate Health Index in detecting clinically significant prostate cancer in the PI-RADS 3 population: a multicenter prospective study.前列腺健康指数在检测PI-RADS 3人群中临床显著前列腺癌的作用:一项多中心前瞻性研究。
World J Urol. 2023 Feb;41(2):455-461. doi: 10.1007/s00345-022-04272-0. Epub 2023 Jan 2.
9
Clinical Utility of Prostate Health Index for Diagnosis of Prostate Cancer in Patients with PI-RADS 3 Lesions.前列腺健康指数在PI-RADS 3类病变患者前列腺癌诊断中的临床应用价值
Cancers (Basel). 2022 Aug 29;14(17):4174. doi: 10.3390/cancers14174174.
10
Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer.结合前列腺健康指数密度、磁共振成像和既往阴性活检结果改善临床显著前列腺癌的检测。
BJU Int. 2018 Apr;121(4):619-626. doi: 10.1111/bju.14098. Epub 2018 Jan 9.

引用本文的文献

1
Development and validation of multivariable biopsy-free nomograms to predict clinically significant prostate cancer in patients with prostate-specific antigen levels ≥20 ng/mL.用于预测前列腺特异性抗原水平≥20 ng/mL患者临床显著性前列腺癌的多变量无活检列线图的开发与验证
Transl Androl Urol. 2025 Mar 30;14(3):507-518. doi: 10.21037/tau-24-533. Epub 2025 Mar 26.
2
An online clustering algorithm predicting model for prostate cancer based on PHI-related variables and PI-RADS in different PSA populations.一种基于不同前列腺特异性抗原(PSA)人群中与前列腺健康指数(PHI)相关变量和前列腺影像报告和数据系统(PI-RADS)的前列腺癌在线聚类算法预测模型。
Cancer Cell Int. 2025 Feb 13;25(1):44. doi: 10.1186/s12935-025-03677-2.
3

本文引用的文献

1
Construction and Comparison of Different Models in Detecting Prostate Cancer and Clinically Significant Prostate Cancer.检测前列腺癌及临床显著性前列腺癌不同模型的构建与比较
Front Oncol. 2022 Jul 12;12:911725. doi: 10.3389/fonc.2022.911725. eCollection 2022.
2
Cancer statistics, 2022.癌症统计数据,2022 年。
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
3
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
Development and validation of biopsy free nomograms for predicting clinically significant prostate cancer in men with PI-RADS 4 and 5 lesions.
用于预测PI-RADS 4和5类病变男性患者临床显著性前列腺癌的非活检列线图的开发与验证
Sci Rep. 2025 Jan 20;15(1):2506. doi: 10.1038/s41598-025-86607-6.
4
Optimizing prostate biopsy decision-making for patients with Prostate Imaging-Reporting and Data System (PI-RADS) ≥3 lesions: novel magnetic resonance imaging (MRI)-based nomograms.优化前列腺影像报告和数据系统(PI-RADS)≥3级病变患者的前列腺活检决策:基于磁共振成像(MRI)的新型列线图
Quant Imaging Med Surg. 2024 Dec 5;14(12):8196-8210. doi: 10.21037/qims-24-1072. Epub 2024 Oct 11.
5
Incorporating PHI in decision making: external validation of the Rotterdam risk calculators for detection of prostate cancer.将 PHI 纳入决策制定中:用于前列腺癌检测的鹿特丹风险计算器的外部验证。
World J Urol. 2024 Mar 13;42(1):141. doi: 10.1007/s00345-024-04833-5.
EAU-EANM-ESTRO-ESUR-SIOG 前列腺癌指南-2020 版更新。第 1 部分:筛查、诊断和以治愈为目的的局部治疗。
Eur Urol. 2021 Feb;79(2):243-262. doi: 10.1016/j.eururo.2020.09.042. Epub 2020 Nov 7.
4
Prostate Health Index and Prostate Health Index Density as Diagnostic Tools for Improved Prostate Cancer Detection.前列腺健康指数和前列腺健康指数密度作为提高前列腺癌检测的诊断工具。
Biomed Res Int. 2020 Jul 21;2020:9872146. doi: 10.1155/2020/9872146. eCollection 2020.
5
Development and validation of a nomogram including lymphocyte-to-monocyte ratio for initial prostate biopsy: a double-center retrospective study.建立并验证包括淋巴细胞与单核细胞比值的列线图在初次前列腺穿刺活检中的应用:一项双中心回顾性研究。
Asian J Androl. 2021 Jan-Feb;23(1):41-46. doi: 10.4103/aja.aja_19_20.
6
Prostate Health Index and multiparametric magnetic resonance imaging to predict prostate cancer grade reclassification in active surveillance.前列腺健康指数和多参数磁共振成像预测主动监测中前列腺癌分级再分类。
BJU Int. 2020 Sep;126(3):373-378. doi: 10.1111/bju.15101. Epub 2020 Jun 2.
7
Review article: MRI-targeted biopsies for prostate cancer diagnosis and management.综述文章:用于前列腺癌诊断和管理的 MRI 靶向活检。
World J Urol. 2021 Jan;39(1):57-63. doi: 10.1007/s00345-020-03182-3. Epub 2020 Apr 6.
8
Comparison of complications after transrectal and transperineal prostate biopsy: a national population-based study.经直肠和经会阴前列腺活检术后并发症的比较:一项全国基于人群的研究。
BJU Int. 2020 Jul;126(1):97-103. doi: 10.1111/bju.15039. Epub 2020 Apr 6.
9
A novel nomogram combined PIRADS v2 and neutrophil-to-lymphocyte ratio to predict the risk of clinically significant prostate cancer in men with PSA < 10 ng/ml at first biopsy.一种新的列线图,结合了 PIRADS v2 和中性粒细胞与淋巴细胞比值,用于预测首次活检时 PSA<10ng/ml 的男性中临床显著前列腺癌的风险。
Urol Oncol. 2020 May;38(5):401-409. doi: 10.1016/j.urolonc.2019.12.006. Epub 2019 Dec 23.
10
Development and internal validation of a novel PHI-nomogram to identify aggressive prostate cancer.开发并内部验证一种新型 PHI 列线图以识别侵袭性前列腺癌。
Clin Chim Acta. 2020 Feb;501:174-178. doi: 10.1016/j.cca.2019.10.039. Epub 2019 Nov 20.